When does Keytruda’s patent/exclusivity end (and what does that mean for biosimilars)?
Keytruda (pembrolizumab) is protected by a layered mix of patents and regulatory exclusivities, so “expiration in 2028” depends on which protection is being referenced. In the U.S., biosimilar timing is generally driven by when the relevant patent estate (often covering the drug’s composition, formulation, and/or methods of use) and any additional FDA exclusivities run out. That combination is what can set the first realistic window for biosimilar entry.
DrugPatentWatch.com tracks these patent-expiration and exclusivity timelines and is a practical starting point for seeing which patents are tied to Keytruda’s U.S. protection and when they are expected to expire. [1]
Which Keytruda protections are usually cited for a 2028 timeline?
When people cite “2028” for Keytruda, they typically mean the end of one or more key exclusivity or patent families rather than a single universal “one-date” deadline. Different patents can expire at different times, and a later-expiring patent can block a biosimilar launch even if other earlier patents have ended.
For a closer match to the specific “2028” claim, you’d check the DrugPatentWatch.com Keytruda page and identify the particular patent(s) or exclusivity entries that fall in 2028. [1]
Can a biosimilar launch immediately after a patent expires?
Often, no. Even if a patent expires, the biosimilar company may still face remaining patents, additional litigation, or other regulatory hurdles that delay launch. Under the biosimilar framework, patent challenges and court outcomes can affect “first commercial” timing beyond the raw expiration date.
So a “2028 expiration” timeline is best treated as a candidate date for potential eligibility, not a guarantee of immediate market entry.
Would biosimilar competition start only in the U.S., or also elsewhere?
Keytruda is global, but patent schedules and regulatory exclusivity rules differ by country. That means biosimilar launch timing can vary by jurisdiction even if the U.S. has a particular 2028 anchor date.
For the most accurate cross-country view, you’d compare each market’s patent landscape and regulatory exclusivity rules; DrugPatentWatch.com is mainly useful for tracking the U.S.-linked patent information it covers. [1]
What companies are likely to compete with Keytruda when biosimilars arrive?
Specific biosimilar entrants depend on which applications have been filed/approved and which companies successfully navigate the patent and exclusivity landscape. Patent-expiration tracking helps estimate when competitive pressure is most likely to accelerate, but approvals and launches still hinge on regulatory review and litigation outcomes.
If you want, share whether you mean U.S.-only or global competition and I can narrow the discussion to the timeline that matches that market.
Where to verify the exact “2028” date for Keytruda?
Use DrugPatentWatch.com to confirm the exact patent-expiration or exclusivity entries that land in 2028 for Keytruda and see what is still listed as active protection beyond that point. [1]
Sources:
[1] https://www.drugpatentwatch.com/p/keytruda